{"id":"W4385779498","doi":"10.1007/s12325-023-02606-x","title":"Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Oncology; ALK inhibitor; Lung cancer; Interim analysis; Tyrosine-kinase inhibitor; Progression-free survival; Metastasis; Clinical trial; Cancer; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001155393,0.0004577318,0.000677089,0.0005425689,0.000850569,0.002716975,0.0009061435,0.00269472,0.02641769],"category_scores_gemma":[0.003364957,0.0002520603,0.00084316,0.000444269,0.0006012672,0.001515756,0.0008973697,0.005969571,0.006739156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001367339,"about_ca_system_score_gemma":0.001462114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001494235,"about_ca_topic_score_gemma":0.006326185,"domain_scores_codex":[0.9995185,0.0001022856,0.00004004047,0.00006028525,0.0001900332,0.00008885424],"domain_scores_gemma":[0.9982667,0.0004249905,0.0002944892,0.00007393145,0.0003937478,0.0005460779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007057408,0.00009335175,0.0001818349,0.0003879685,0.00001955054,0.0001947866,0.00001416888,0.0001536429,0.0009241061,0.001781007,0.8968122,0.09873164],"study_design_scores_gemma":[0.0003993932,0.0003505466,0.001334167,0.0004180387,0.00003530124,0.0002934551,0.00001797208,0.0002568337,0.000381003,0.0009982155,0.9954977,0.00001742725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.01139036,0.184106,0.003543828,0.2926449,0.333318,0.0007282288,0.0048322,0.001481875,0.1679546],"genre_scores_gemma":[0.06913789,0.1988042,0.005125043,0.1590996,0.3273297,0.0004980043,0.004361372,0.0006083737,0.2350358],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02641769,"threshold_uncertainty_score":0.08837605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02005702054535472,"score_gpt":0.364229775795692,"score_spread":0.3441727552503372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}